Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

7 evidence topics · 7 sources

SOL-1: aflibercept loading doses before randomization

“Under the study protocol, after initial screening, every enrolled subject received two aflibercept 2 mg loading doses between the screening visit and Day 1: one at Week -8 and another at Week -4.” (opens the source at this quote in a new tab)

SOL-1: supplemental aflibercept rescue

“Our pre-specified rescue criteria are a loss of 15 or more letters on the ETDRS chart compared to baseline due to wet AMD, or a new hemorrhage that is deemed to be likely to cause irreversible vision loss due to progression of wet AMD.” (opens the source at this quote in a new tab)

“The protocol provides that after the first rescue injection, rescue therapy may be provided at investigator discretion per their clinical judgement.” (opens the source at this quote in a new tab)

SOL-R: anti-VEGF screening doses, aflibercept loading, and rescue criteria

“Over the six month screening and lead-in period prior to Baseline (Day 1) randomization, enrolled subjects were given three screening doses of any anti-VEGF therapy, excluding brolucizumab-dbll, and two monthly loading doses of aflibercept 2 mg prior to Day 1, and monitored to exclude subjects demonstrating early persistent fluid or significant retinal fluid fluctuations.” (opens the source at this quote in a new tab)

“The pre-specified rescue criteria include a loss of more than 5 ETDRS letters in BCVA from best recorded prior visit (baseline or later) due to wet AMD, combined with an increase of 75 microns or more in CSFT from prior lowest measurement (baseline or later) due to wet AMD.” (opens the source at this quote in a new tab)

Phase 1 trials: concomitant anti-VEGF injection

“Experimental: Cohort 3 (Anti-VEGF) Subjects will receive OTX-TKI plus a single anti-VEGF injection” (opens the source at this quote in a new tab)

U.S. phase 1 trial: prior anti-VEGF treatment requirement

“Must have received at least 3 anti-VEGF injections in the past year.” (opens the source at this quote in a new tab)

Topical corticosteroids for intraocular inflammation in SOL-1

“8 events treated with topical corticosteroids and resolved” (opens the source at this quote in a new tab)

Prophylactic corticosteroids with implant administration

“Most importantly, retina specialists would not need to change anything about how they treat patients today – no surgery, no concomitant steroids, no new procedures.” (opens the source at this quote in a new tab)

Concomitant systemic medication use in studied participants

No evidence found.